Initiating therapy in patients newly diagnosed with type 2 diabetes: Combination therapy vs a stepwise approach
- PMID: 28862799
- DOI: 10.1111/dom.13108
Initiating therapy in patients newly diagnosed with type 2 diabetes: Combination therapy vs a stepwise approach
Abstract
There is clear evidence that achieving glycaemic targets reduces the risk of developing complications as a result of type 2 diabetes (T2D). Many patients, however, continue to have suboptimal glycaemic control because of issues that include unclear advice on how to achieve these targets as well as clinical inertia. The two management approaches recommended for patients newly diagnosed with T2D are stepwise and combination therapy, each of which has advantages and disadvantages. Stepwise therapy may result in good patient adherence and allow greater individualization of therapy, and minimization of side effects and cost, and so may be appropriate for patients who are closer to goal. Stepwise therapy, however, may also lead to frequent delays in achieving glycaemic goals and longer exposure to hyperglycaemia. Combination therapy, which is now emerging as an important therapy option, has a number of potential advantages over stepwise therapy, including reduction in clinical inertia and earlier and more frequent achievement of glycated haemoglobin goals by targeting multiple pathogenic mechanisms simultaneously, which may more effectively delay disease progression. Compared with stepwise therapy, the disadvantages of combination therapy include reduced patient adherence resulting from complex, multi-drug regimens, difficulty determining the cause of poor efficacy and/or side effects, patient refusal to accept disease, and higher cost. Fixed-dose and fixed-ratio combinations are novel therapeutic approaches which may help address several issues of treatment complexity and patient burden associated with combination therapy comprising individual drugs. The choice of which drugs to administer and the decision to use stepwise vs combination therapy, however, should always be made on an individualized basis.
Keywords: combination therapy; glycaemic control; newly diagnosed; stepwise therapy; type 2 diabetes; β-cell function.
© 2017 John Wiley & Sons Ltd.
Similar articles
-
Improvement in glycaemic control with rosiglitazone/metformin fixed-dose combination therapy in patients with type 2 diabetes with very poor glycaemic control.Diabetes Obes Metab. 2006 Nov;8(6):643-9. doi: 10.1111/j.1463-1326.2006.00648.x. Diabetes Obes Metab. 2006. PMID: 17026488 Clinical Trial.
-
Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.Pharmacoeconomics. 2004;22(6):389-411. doi: 10.2165/00019053-200422060-00005. Pharmacoeconomics. 2004. PMID: 15099124 Review.
-
Oral antidiabetic agents: current role in type 2 diabetes mellitus.Drugs. 2005;65(3):385-411. doi: 10.2165/00003495-200565030-00005. Drugs. 2005. PMID: 15669880 Review.
-
Does rapid transition to insulin therapy in subjects with newly diagnosed type 2 diabetes mellitus benefit glycaemic control and diabetes-related complications? A German population-based study.Exp Clin Endocrinol Diabetes. 2006 Oct;114(9):520-6. doi: 10.1055/s-2006-951779. Exp Clin Endocrinol Diabetes. 2006. PMID: 17115350
-
Improving glucose management: ten steps to get more patients with type 2 diabetes to glycaemic goal.Int J Clin Pract. 2005 Nov;59(11):1345-55. doi: 10.1111/j.1742-1241.2005.00674.x. Int J Clin Pract. 2005. PMID: 16236091
Cited by
-
Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy.Signal Transduct Target Ther. 2024 Oct 2;9(1):262. doi: 10.1038/s41392-024-01951-9. Signal Transduct Target Ther. 2024. PMID: 39353925 Free PMC article. Review.
-
A Review on Affordable Combinations in Type 2 Diabetes Care: Exploring the Cost-Effective Potential of Glipizide + Metformin and Glimepiride + Metformin + Pioglitazone.Cureus. 2024 May 7;16(5):e59850. doi: 10.7759/cureus.59850. eCollection 2024 May. Cureus. 2024. PMID: 38854289 Free PMC article. Review.
-
Two-Year Therapeutic Efficacy and Safety of Initial Triple Combination of Metformin, Sitagliptin, and Empagliflozin in Drug-Naïve Type 2 Diabetes Mellitus Patients.Diabetes Metab J. 2024 Mar;48(2):253-264. doi: 10.4093/dmj.2023.0128. Epub 2024 Jan 26. Diabetes Metab J. 2024. PMID: 38273791 Free PMC article.
-
2023 TAMIS/TSOC/TACVPR Consensus Statement for Patients with Acute Myocardial Infarction Rehabilitation.Acta Cardiol Sin. 2023 Nov;39(6):783-806. doi: 10.6515/ACS.202311_39(6).20230921A. Acta Cardiol Sin. 2023. PMID: 38022422 Free PMC article.
-
[Luces y sombras de la Guía Europea esc-2021 de Prevención de la Enfermedad Cardiovascular en la Práctica Clínica.].Rev Esp Salud Publica. 2023 Aug 16;97:e202308064. Rev Esp Salud Publica. 2023. PMID: 37921403 Free PMC article. Spanish.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical